Viquipèdia

Vaccí contra la COVID-19: diferència entre les revisions

Exploració interactiva de l'historial
← Edició anteriorEdició següent →
Contingut suprimit Contingut afegit
VisualWikitext
Línia 231:
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=131
|status=Resposta amb adjuvant després de [[dosi de reforç]] d'[[Immunoglobulina G|IgG]] i [[anticòs neutralitzant]]<ref name="pmid32877576">{{ref-publicació| vauthors = Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM | display-authors=6 |títol= Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine |publicació= The New England Journal of Medicine |data= setembre 2020 |volum=383 |exemplar=24 |pàgines=2320–2332 | pmid = 32877576 | pmc = 7494251 | doi = 10.1056/NEJMoa2026920}}</ref>}}
|{{Collapsible list|title=Emergència (76+27=33)|expand=yes
<section begin="E_Novavax"/>
| [[Austràlia]]<ref>{{ref-web|títol=Novavax COVID vaccine takes first step toward Australian approval|url=https://www.raps.org/news-and-articles/news-articles/2021/1/novavax-covid-vaccine-takes-first-step-toward-aust|access-date=2021-04-01|website=www.raps.org}}</ref>
Línia 241:
<section end="E_Novavax"/>
| [[Nova Zelanda]]<ref>{{ref-web|cognom=biopharma-reporter.com|títol=New Zealand secures COVID-19 vaccines from Novavax and AstraZeneca|url=https://www.biopharma-reporter.com/Article/2020/12/17/New-Zealand-secures-COVID-19-vaccines-from-Novavax-and-AstraZeneca|access-date=2021-04-01|website=biopharma-reporter.com|llengua=en-GB}}</ref>
}}▼
|- valign="top"▼
|'''[[Vacuna de Sanofi–GSK contra la COVID-19|Vacuna de Sanofi–GSK]]''' <small>(VAT00002)</small><br />[[Sanofi Pasteur]], [[GlaxoSmithKline|GSK]]
|França, Regne Unit▼
|[[Vacuna#Vacunes_de_subunitats|De subunitats]]▼
|{{ClinicalStudyInfo|align=left|phase=3|participants=34520|references=<ref>{{cite web |title=Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older. |url=https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475 |website=pactr.samrc.ac.za |publisher=Pan African Clinical Trials Registry |access-date=24 March 2021 |url-status=live}}</ref>|description=Eficàcia, immunogenicitat i seguretat de la vacuna en adults de 18 anys o més.
|whenwhere=Nov Des 2020 {{snd}}Mai 2021Abr 2022, CubaKenya▼
}}▼
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=1160|description=Fase I-IIa (440): Immunogenicitat i seguretat de les formulacions de vacunes de proteïna recombinant SARS-CoV-2 (amb o sense adjuvant) en adults sans de 18 anys o més.<ref>{{ref-cite web |títoltitle=Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older |url=https://clinicaltrials.gov/ct2/show/NCT04537208 |website=clinicaltrials.gov |editorpublisher=United States National Library of Medicine |access-date= 11 marçMarch 2021 |url-status=live}}</ref><br />Fase IIb (720): Immunogenicitat i seguretat de la vacuna de proteïna recombinant SARS-CoV-2 amb adjuvant AS03 en adults de 18 anys o més.<ref>{{ref-cite web |títoltitle=Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002) |url=https://clinicaltrials.gov/ct2/show/NCT04762680 |website=clinicaltrials.gov |editorpublisher=United States National Library of Medicine |access-date= 11 marçMarch 2021 |url-status=live}}</ref>▼
|whenwhere=MarSet 2020{{snd}}JulSet 20212022, CubaEstats Units▼
}}▼
|{{Collapsible list| title = Emergència (23+27=31) | expand = yes▼
| [[Canadà]]<ref>{{Cite web|title=Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine {{!}} GSK|url=https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/|access-date=2021-04-01|website=www.gsk.com|language=en-GB}}</ref>▼
| [[EUA]]<ref>{{Cite news|date=2020-05-13|title=U.S. Likely to Get Sanofi Vaccine First If It Succeeds|language=en|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2020-05-13/u-s-to-get-sanofi-covid-vaccine-first-if-it-succeeds-ceo-says|access-date=2021-04-01}}</ref>
| [[Regne Unit]]<ref>{{Cite news|date=2020-07-29|title=Coronavirus vaccine: UK signs deal with GSK and Sanofi|language=en-GB|work=BBC News|url=https://www.bbc.com/news/business-53577637|access-date=2021-04-01}}</ref>
| [[Unió Europea]]<ref>{{Cite web|title=Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine {{!}} GSK|url=https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/|access-date=2021-04-01|website=www.gsk.com|language=en-GB}}</ref>▼
}}
|- valign="top"
Linha 257 ⟶ 273:
|duration=Jun 2020{{snd}}Oct 2021
}}
|{{Collapsible list| title = Emergència (127) | expand = yes
| [[Unió Europea|UE]]<ref name="EU CVnCoV rolling review">{{cite press release|title=EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)|website=[[European Medicines Agency]] (EMA)|date=1 desembre 2020|url=https://www.ema.europa.eu/en/news/ema-starts-rolling-review-curevacs-covid-19-vaccine-cvncov|access-date= 12 febrer 2021}}</ref>
}}
▲|- valign="top"
|'''[[CIGB-66]]''' <small>(ABDALA)</small><br />[[:es:Centro de Ingeniería Genética y Biotecnología de Cuba|Centre d'Ingenieria Genètica i Biotecnologia]]
|Cuba▼
▲|[[Vacuna#Vacunes_de_subunitats|De subunitats]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=48000|references=<ref>{{ref-web|títol=ABDALA Clinical Study - Phase III |url=https://rpcec.sld.cu/en/trials/RPCEC00000359-En |website=rpcec.sld.cu |editor=Registro Público Cubano de Ensayos Clínicos |access-date= 22 març 2021 |url-status=live}}</ref>|description=Multicèntric, aleatoritzat, doble cec, controlat amb placebo.▼
▲|whenwhere=Mar {{snd}}Jul 2021, Cuba
▲}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=132|references=<ref>{{ref-web|títol=ABDALA Clinical Study |url=https://rpcec.sld.cu/en/trials/RPCEC00000346-En |website=rpcec.sld.cu |editor=Registro Público Cubano de Ensayos Clínicos |access-date= 21 març 2021 |url-status=live}}</ref>|description=Aleatoritzat, doble cec, controlat amb placebo, factorial.
▲|whenwhere=Nov 2020 {{snd}}Mai 2021, Cuba
▲}}
|▼
|- valign="top"
|'''[[SOBERANA 02]]''' <small>(FINLAY-FR-2)</small><wbr /><br />Institut Finlay de Vacunes
Linha 283 ⟶ 288:
|whenwhere=Nov 2020{{snd}}Mar 2021, Cuba
}}
|{{Collapsible list | title=Emergència (1) | expand=yes
|▼
| [[Cuba]]<ref>{{Cite journal|date=2021-03-29|title=Production of the vaccine Soberana 02 in Cuba.|url=https://www.bmj.com/content/372/bmj.n171/rr-0|language=en|pages=n171}}</ref>
}}
|- valign="top"
|'''[[Vacuna de Sanofi–GSK contra la COVIDCIGB-1966]]''' <small>(VAT00002ABDALA)</small><br />[[Sanofi:es:Centro Pasteur]],de [[GlaxoSmithKlineIngeniería Genética y Biotecnología de Cuba|GSKCentre d'Ingenieria Genètica i Biotecnologia]]
▲|Cuba
▲|França, Regne Unit
|[[Vacuna#Vacunes_de_subunitats|De subunitats]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=3452048000|references=<ref>{{ref-web|títol=StudyABDALA ofClinical RecombinantStudy Protein Vaccine with Adjuvant against COVID-19 inPhase Adults 18 Years of Age and Older.III |url=https://pactrrpcec.samrcsld.ac.zacu/TrialDisplay.aspx?TrialID=13475en/trials/RPCEC00000359-En |website=pactrrpcec.samrcsld.ac.zacu |editor=PanRegistro AfricanPúblico ClinicalCubano Trialsde RegistryEnsayos Clínicos |access-date= 2422 març 2021 |url-status=live}}</ref>|description=EficàciaMulticèntric, immunogenicitataleatoritzat, idoble seguretatcec, de la vacuna de proteïna recombinant SARS-CoV-2controlat amb adjuvant en adults de 18 anys o mésplacebo.
|whenwhere= Des 2020Mar {{snd}}Jul Abr 20222021, KenyaCuba
}}
▲|{{ClinicalStudyInfo|align=left|phase=31|endphase=2|participants=48000132|references=<ref>{{ref-web|títol=ABDALA Clinical Study - Phase III |url=https://rpcec.sld.cu/en/trials/RPCEC00000359RPCEC00000346-En |website=rpcec.sld.cu |editor=Registro Público Cubano de Ensayos Clínicos |access-date= 2221 març 2021 |url-status=live}}</ref>|description=Multicèntric, aleatoritzatAleatoritzat, doble cec, controlat amb placebo, factorial.
▲|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=1160|description=Fase I-IIa (440): Immunogenicitat i seguretat de les formulacions de vacunes de proteïna recombinant SARS-CoV-2 (amb o sense adjuvant) en adults sans de 18 anys o més.<ref>{{ref-web|títol=Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older |url=https://clinicaltrials.gov/ct2/show/NCT04537208 |website=clinicaltrials.gov |editor=United States National Library of Medicine |access-date= 11 març 2021 |url-status=live}}</ref><br />Fase IIb (720): Immunogenicitat i seguretat de la vacuna de proteïna recombinant SARS-CoV-2 amb adjuvant AS03 en adults de 18 anys o més.<ref>{{ref-web|títol=Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002) |url=https://clinicaltrials.gov/ct2/show/NCT04762680 |website=clinicaltrials.gov |editor=United States National Library of Medicine |access-date= 11 març 2021 |url-status=live}}</ref>
|whenwhere=SetNov 2020 {{snd}}SetMai 20222021, Estats UnitsCuba
▲}}
▲|{{Collapsible list| title = Emergència (2) | expand = yes
▲ | [[Unió Europea]]<ref>https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/</ref>
▲ | [[Canadà]]<ref>https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/</ref>
}}
▲|
|- valign="top"
|''Sense nom''<wbr /><ref name="NCT04412538">{{ref-web|títol=Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04412538 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04412538 |data= 2 juny 2020 |access-date= 14 juliol 2020}}</ref><br />[[Col·legi de Medicina de la Unió de Pequín|Acadèmia Xinesa de Ciències Mèdiques]]
Linha 323 ⟶ 327:
|
|- valign="top"
|'''[[ZyCoV-D]]'''<wbr /><ref name=":4">{{ref-web|website=ctri.nic.in|editor=[[Clinical Trials Registry – India|Clinical Trials Registry India]]|títol=A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects|type=Registry |id=CTRI/2020/07/026352 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306|url-status=live|arxiuurl=https://web.archive.org/web/20201122022620/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306|arxiudata= 22 novembre 2020|data=15 desembre 2020}}</ref><br />[[Cadila Healthcare]]
[[Cadila Healthcare]]
|Índia
|[[Vacuna d'ADN|Plàsmid d'ADN]] expressant la [[Proteïna S del SARS-CoV-2|proteïna S]]
Linha 422 ⟶ 425:
|
|- valign="top"
|''Sense'[[Vacuna nomde Minhai contra la COVID-19|Vacuna de Minhai]]'''<br />Minhai Biotechnology Co.
|Xina
|[[Vacuna inactivada|Inactivada]] (cèl·lules vero)
Linha 435 ⟶ 438:
|
|- valign="top"
|'''[[DelNS1-2019-nCoV-RBD-OPT]]'''<br />Beijing Wantai Biological Pharmacy
|Xina
|[[Vector víric]]
Linha 459 ⟶ 462:
|
|- valign="top"
|''Sense'[[Vacuna nomde Walvax contra la COVID-19|Vacuna de Walvax]]'''<wbr/><ref name="ChiCTR2000034112">{{ref-web|url=http://www.chictr.org.cn/showprojen.aspx?proj=55524 |títol=A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above |website=Chinese Clinical Trial Register |id=ChiCTR2000034112 |data= 24 juny 2020 |access-date= 6 juliol 2020 |arxiudata= 11 octubre 2020 |arxiuurl=https://web.archive.org/web/20201011085018/http://www.chictr.org.cn/showprojen.aspx?proj=55524%2F |url-status=live}}</ref><br />[[Acadèmia de Ciències Militars de l'Exèrcit Popular d'Alliberament]], Walvax Biotech<ref name="walvax">{{ref-web|url=http://www.walvax.com/wosen/28.aspx |títol=Company introduction |website=Walvax Biotechnology |access-date= 1 agost 2020 |arxiudata= 11 octubre 2020 |arxiuurl=https://web.archive.org/web/20201011085028/http://www.walvax.com/wosen/28.aspx/ |url-status=live}}</ref>
|Xina
|[[Vacuna d'ARN|ARN]]
Linha 467 ⟶ 470:
|{{ClinicalStudyInfo|align=left|phase=1|participants=168
|whenwhere=Jun 2020{{snd}}Des 2021, Xina
}}
▲|
|- valign="top"
|'''[[ERUCOV-VAC]]'''<br />[[Ministeri de Salut (Turquia)|Instituts de Salut de Turquia]]
|Turquia
|[[Vacuna inactivada|Inactivada]]
|{{ClinicalStudyInfo|align=left|phase=2|participants=250|references=<ref>{{cite web |title=Eficàcia, immunogenicitat i seguretat en comparació amb placebo per la COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04824391 |website=clinicaltrials.gov |publisher=United States National Library of Medicine |access-date=4 April 2021 |url-status=live}}</ref>|description=Estudi de la fase 2 per a la determinació de l'eficàcia, la immunogenicitat i la seguretat de dos punts forts diferents de la vacuna, en un disseny d'estudi doble cec controlat, aleatoritzat i placebo.
|whenwhere=Feb {{snd}}Abr 2021, Turquia
}}
|{{ClinicalStudyInfo|align=left|phase=1|participants=44|references=<ref>{{cite web |title=Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC) |url=https://clinicaltrials.gov/ct2/show/NCT04691947 |website=clinicaltrials.gov |publisher=United States National Library of Medicine |access-date=21 March 2021 |url-status=live}}</ref>|description=Estudi per a la determinació de la seguretat i la immunogenicitat de dos punts forts diferents de la vacun, administrada dues vegades per via intramuscular a voluntaris sans, en un disseny d'estudi controlat amb placebo.
|whenwhere=Nov 2020 {{snd}}Mar 2021, Turquia
}}
|
Linha 498 ⟶ 512:
 
{{notelist-la}}
 
 
== Eficàcia ==
Obtingut de «https://ca.wikipedia.org/wiki/Vaccí_contra_la_COVID-19»